Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
Moodys
Johnson and Johnson
Harvard Business School
Mallinckrodt

Last Updated: January 31, 2023

Investigational Drug Information for TVB-2640


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for TVB-2640?

TVB-2640 is an investigational drug.

There have been 10 clinical trials for TVB-2640. The most recent clinical trial was a Phase 2 trial, which was initiated on November 18th 2021.

The most common disease conditions in clinical trials are Non-alcoholic Fatty Liver Disease, Liver Diseases, and Fatty Liver. The leading clinical trial sponsors are Sagimet Biosciences Inc., Ascletis Pharmaceuticals Co., Ltd., and 3V Biosciences, Inc.

There is one US patent protecting this investigational drug and one hundred and eight international patents.

Recent Clinical Trials for TVB-2640
TitleSponsorPhase
A Phase I, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-TVB-2640 Following a Single Oral Dose in Healthy Male SubjectsSagimet Biosciences Inc.Phase 1
Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBMAscletis Pharmaceuticals Co., Ltd.Phase 3
Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)Sagimet Biosciences Inc.Phase 2

See all TVB-2640 clinical trials

Clinical Trial Summary for TVB-2640

Top disease conditions for TVB-2640
Top clinical trial sponsors for TVB-2640

See all TVB-2640 clinical trials

International Patents for TVB-2640

Drugname Country Document Number Estimated Expiration Related US Patent
TVB-2640 Canada CA2979696 2035-03-19 See Plans and Pricing
TVB-2640 China CN107428728 2035-03-19 See Plans and Pricing
TVB-2640 European Patent Office EP3277675 2035-03-19 See Plans and Pricing
TVB-2640 Spain ES2910049 2035-03-19 See Plans and Pricing
TVB-2640 Japan JP2018508547 2035-03-19 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
Moodys
Johnson and Johnson
Harvard Business School
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.